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The use of specific combinations of antigens and adjuvant represents a promising approach for increasing 
the immunogenicity of DNA vaccines. In the present study, we evaluated the immunity and antitumor 
effects of DNA vaccines with G250 as the target antigen in a mouse model of renal cell carcinoma. 
We constructed two recombinant plasmids, pVAX1-G250 and pVAX1-CD40L. The recombinant 
plasmids were injected into mice by intramuscular injection and electrical pulse stimulation. ELISA 
and ELISPOT experiments were performed to evaluate the corresponding humoral and cellular immune 
responses following immunization. To further investigate the antitumor potential of the DNA vaccines, 
we established a tumor-bearing mouse model expressing G250 target antigen. Our results showed that 
immunization with the combination of the two plasmids exerted the strongest anti-tumor effects. Therefore, 
our findings demonstrated the effectiveness of CD40L as an adjuvant for DNA vaccines and highlighted 
the promising use of these vaccines for the treatment of tumors. 
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INTRODUCTION
Renal cell carcinoma (RCC) is the most common 
malignant tumor affecting the kidneys in adults. RCC has 
the second highest incidence among urinary system tumors 
and accounts for 3% of adult systemic malignancies. The 
incidence of renal cell carcinoma continues to increase 
each year (Chander et al., 2015). Surgical treatment 
remains the primary treatment for renal cancer. Renal 
cancer is not sensitive to radiotherapy, chemotherapy, and 
hormone therapy, leading to generally poor prognosis. 
Therefore, early diagnosis and effective postoperative 
adjuvant therapies are particularly important for RCC 
(Courthod et al., 2015). Studies have shown that G250 
exhibits good tumor specificity. Furthermore, 98% of 
primary renal cell carcinoma cases showed overexpression 
of the G250 antigen. In particular, the G250 antigen is 
overexpressed in all renal clear cell carcinoma tissues but 
is not expressed in normal renal tissues (Sun et al., 2014). 
G250 plays an important role in the survival, growth, and 
metastasis of renal tumor cells and is thus considered an 
ideal tumor-associated antigen (TAA). Therefore, G250 
exhibits good potential for the early diagnosis, prognosis, 
and adjuvant therapy of RCC (Lu et al., 2014).
In recent years, DNA vaccines have been widely 
explored in the field of cancer treatment as a new method 
of immunotherapy. DNA vaccines exhibit important 
advantages, such as safety, high specificity, and easy 
industrialization and have thus become an important 
development direction in the immunotherapy of renal 
cancer (Sun et al., 2014; Lan et al., 2013). DNA vaccines 
are generally well tolerated and are mildly immunogenic. 
Therefore, research has focused on methods for improving 
the immunogenicity and anti-tumor effects of vaccines.
Cytokines can be used to activate immune cells, and 
most studies have focused on improving immunity through 
cytokines (Iurescia, Fioretti, Rinaldi, 2014). CD40L, also 
known as CD154, is a member of the tumor necrosis factor 
family, which are mainly expressed by activated CD4+T 
lymphocytes (Gupta et al., 2014). The interaction between 
CD40L and CD40 can directly inhibit the growth of human 
breast, ovarian, cervical and bladder cancers. In addition, 
CD40L can induce phenotype maturation and function 
of DC cells, as well as enhance anti-tumor immunity by 
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upregulating the expression of co-stimulatory factors and 
cytokines (Gupta et al., 2015).
Therefore, we reasoned that co-delivery of CD40L 
could serve as a feasible strategy for improving the efficacy 
of DNA vaccines. We aimed to enhance the effect of anti-
tumor DNA vaccines based on G250 as target antigen in 
a renal carcinoma mouse model. We used CD40L as an 
immune adjuvant and verified its immunogenicity and 
antitumor effects.
MATERIAL AND METHODS 
Animals, cell lines, and antibodies
BALB/c female mice (six to eight weeks old) 
were purchased from Vital River Laboratory Animal 
Technology Co., Ltd (Beijing, China). The mice were 
maintained in accordance with the Guide for the Care 
and Use of Laboratory Animal handling and experimental 
protocols were approved by the ethics committee of 
Daqing Oilfield General Hospital (Approval number: 
20160805007). The murine renal carcinoma (renca) cell 
line was purchased from the Institute of Basic Medical 
Sciences, Chinese Academy of Medical Sciences 
(Beijing, China). Antibodies targeting the mouse CD40L 
(GTX75095, GeneTex Inc., USA) and human G250 
(Q16790, R&D Systems, USA) antigens were used for 
immunofluorescence analysis.
Construction and expression of DNA vaccines
The coding region of CD40L (M12036.1) and the 
coding region of G250 (GenBank: NM_001216.2) were 
synthesized by Invitrogen. Afterwards, the two genes were 
directly cloned into the eukaryotic expression plasmid 
vector pVAX1 (Figure 1). Two different expression 
plasmids were generated, namely, pVAX1- G250 and 
pVAX1- CD40L, corresponding to the G250 and CD40L 
antigens, respectively. The plasmid DNA was transformed 
into Escherichia coli DH5α cells, purified from large-scale 
cultures using a TIANGEN Endo-free kit (catalog number: 
DP120-01, TIANGEN, Beijing, China), and suspended in 
sterile saline.
To evaluate the expression of these plasmids, 
they were transiently transfected into 293T cells, and 
immunofluorescence analysis was performed to confirm 
the antigen expression of the constructs. Briefly, 293T 
cells were collected at 48 h after transfection. Cells were 
washed with washing buffer, treated with anti-CD40L 
or anti-G250 antibody, and subsequently analyzed by 
immunofluorescence analysis.
Animal treatment groups and DNA immunization
A total of eight BALB/c mice (n=8) were used for 
each experimental group. Mice were vaccinated with 30 
μg of plasmid by intramuscular administration followed 
by electroporation. Vaccination was performed thrice in 
two-week intervals. Electroporation parameters were as 
follows: 120 V/mm distance between the electrodes, 50-
ms pulse length, and six pulses with reversal of polarity 
after each pulse. The BTX 820 electroporator was used for 
the electroporation procedure (Hollison, USA).
FIGURE 1 - Construction of the recombinant plasmids harboring the genes encoding G250 and CD40L.
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Serum antibodies
Anti-G250 antibodies in the sera of immunized 
mice were detected by enzyme linked immunosorbent 
assay (ELISA). Briefly, 96-well microplates were coated 
with 5 μg/ml recombinant G250 protein. After blocking, 
sera were serially diluted in PBS and incubated in the 
plates for 2 h at room temperature. Plates were washed 
and subsequently incubated with a 1:2000 dilution of 
a horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG antibody (Bio-Sen Biological Technology, 
Beijing, China) at room temperature for 1 h. The reaction 
was stopped with 1 M H2SO4, and the absorbance was 
measured at 450 nm.
Enzyme-Linked ImmunoSpot (ELISpot) assay
Splenocytes were isolated from vaccinated groups 
of mice. The IFN-γ Enzyme-Linked ImmunoSpot 
assay (ELISPOT) was performed according to the 
manufacturer’s protocol (Dakewe, Beijing, China). 
Briefly, 96-well plates pre-coated with anti-mouse 
interferon (IFN)-γ monoclonal antibody and blocked for 
1 h at 37 °C. Freshly isolated splenocytes (2 × 105 cells/
well) from each vaccinated mouse were added to the wells 
and incubated with 5 μg/ml recombinant G250 protein 
for 20 h. Assays were performed in triplicate for each 
treatment group.
Cytokine secretion assay
For the cytokine secretion assay, splenocytes were 
prepared and cultured with recombinant G250 protein 
(5 µg/mL) in triplicate following the same procedure as 
that used for the ELISPOT assays. Culture supernatants 
were collected after 72 h. The concentrations of IFN-γ 
and interleukin-4 (IL-4) were measured by ELISA using 
commercial cytokine assay kits (Dakewe, Shenzhen, 
China) according to the manufacturer’s instructions. 
Tumor challenge
Mice were vaccinated thrice with 30 μg of plasmid 
with 14-day intervals between vaccinations. At 7 days 
after the final immunization, mice were subcutaneously 
injected with 2.0×105 renca cells in the right flank. Tumor 
development was monitored in individual mice every 2 
to 3 days. Tumor volumes were calculated according to 
the following formula: V (mm3)= 0.5 × long diameters × 
short diameters 2, and the growth curves of the tumors 
were generated. After the mice were sacrificed, the tumors 
were removed and weighed, and the corresponding tumor 
growth inhibition rates were calculated. 
Statistical analysis
All results were presented as means ± SD. Survival 
curves were analyzed following the Kaplan-Meier method. 
One-way ANOVA was performed to determine significant 
differences between groups. P < 0.05 was considered 
statistically significant.
RESULTS 
Expression of DNA vaccine 
The recombinant DNA plasmids were transfected 
into 293T cells, and expression levels of G250 and 
CD40L were determined by immunofluorescence analysis. 
Experimental results showed that both proteins were 
successfully expressed in mammalian cells (Figure 2).
Humoral and cellular immune responses in mice
At 14 days after the final immunization, mouse sera 
were collected and examined for the production of G250-
specific antibodies. Results revealed that immunization 
with DNA vaccines induced the production of G250-
specific antibodies (Figure 3A).
ELISPOT assays were performed to assess 
the ability of DNA plasmids to prime specific T cell 
responses. Mice were sacrificed at 14 days after the 
third immunization. Splenocytes were prepared and 
stimulated with the recombinant G250 protein. G250-
specific IFN-γ-producing cells were found to be induced 
in the immunized mice. The spot numbers in the two 
vaccinated groups were significantly higher than those in 
the empty vector pVAX1 group. In addition, the number 
of spots in the mice immunized with a combination of 
pVAX1-G250 and pVAX1-CD40L was higher than that 
in the pVAX1-G250 group (Figure 3B). The above results 
indicated that administration with the adjuvant plasmid 
harboring CD40L significantly enhanced the responses of 
the antigen-induced IFN-γ producing cells from the spleen. 
Augmentation of Th1 and Th2 responses
For characterization of the polarization of the 
immune response, IFN-γ and IL-4 levels were measured 
to evaluate Th1 and Th2 cell responses, respectively. As 
shown in Figure 3C, Th1 cytokine (IFN-γ) secretion was 
dramatically higher in the splenocytes of mice immunized 
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FIGURE 2 - Expression of the recombinant plasmid DNA in 293T cells by immunofluorescence analysis.
with both pVAX1-G250 and pVAX1-CD40L than in those 
of pVAX1-G250 group (p<0.05).
In vivo tumor studies 
The effects of immunotherapy were demonstrated by 
measuring tumor size and weight. Tumor growth in mice 
treated with a combination of pVAX1-G250 and pVAX1-
CD40L or pVAX1-G250 alone was more effectively 
inhibited than that in the pVAX1 vector group (Fig. 4A). 
In addition, immunization with the combination of the 
pVAX1-G250 and pVAX1-CD40L vaccines was found to 
more effectively inhibit tumor growth than treatment with 
pVAX1-G250 alone. In addition, tumor weights in mice 
immunized with both vaccines were significantly lower 
than those in pVAX1-G250-immunized mice (Figure 4B). 
DISCUSSION 
Kidney cancer is one of the ten most common 
cancers affecting both men and women. In particular, 
kidney cancer represents 3.7% of all new cancer cases 
and has a worldwide incidence of over 270,000 new cases 
annually (Gill et al., 2016). Over the past 12 years, medical 
treatment for renal cell carcinoma (RCC) has transitioned 
from a nonspecific immune approach (cytokine era), 
targeted therapy against vascular endothelial growth 
factor (VEGF), and currently to novel immunotherapy 
agents. Multiple agents have been approved based on 
effective responses in advanced RCC patients, including 
the following therapies: molecules targeting vascular 
endothelial growth factor, platelet-derived growth factor, 
and related receptors; inhibitors of other targets, such as 
the mammalian target of rapamycin and the MET and 
AXL tyrosine-protein kinase receptors; and an immune-
checkpoint inhibitor (Gill et al., 2016; Marenčák, 
Ondrušová, Ondruš, 2017).
In recent years, gene therapy as adjuvant treatment 
in DNA vaccination has received increasing research 
attention. DNA-based vaccines have several advantages 
over other methods of vaccination because they are 
generally regarded as safe and are relatively simple to 
produce, thereby allowing them to be quickly manufactured 
according to demand (Amara, Tiriveedhi, 2016). In 
addition, DNA plasmid vaccines are relatively stable and 
do not require rigorous cold-chain maintenance, making 
them ideal for deployment applications. Considering that 
cellular immunity appears to be of greater importance than 
humoral immunity for tumor therapy, DNA vaccines have 
also been traditionally considered as effective stimulators 
of cell-mediated immunity and are thus well suited for 
cancer studies (Zahm, Colluru, McNeel, 2017).
To further improve the immunogenicities of the 
DNA vaccines, we combined the CD40L adjuvant plasmid 
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FIGURE 3 - Antibody and T cell responses induced by immunization with the recombinant DNA plasmids in mice. (A) Anti-G250 
antibodies were detected by ELISA. (B) Analysis of spot frequencies of G250-specific IFN-γ-producing T cells. (C) Cytokine 
profiles of proliferating T cells. Data are presented as mean ± S.D. 
FIGURE 4 - Tumor-suppressing effects of immunization with recombinant plasmid DNA in the mouse xenograft model. (A) 
Growth curve of G250® RENCA tumors. (B) Mean tumor weight. Data are presented as mean ± S.D. Mean tumor volumes of 
mice immunized with the combination treatment was significantly smaller than that in mice in the other treatment groups (pVAX1, 
pVAX1-CD40L, or pVAX1-G250).
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with the antigen plasmid. CD40L is primarily expressed 
on mature CD4+ T cells. The interaction between CD40L 
and CD40 is important for T cell-dependent B cell 
activation and isotype switching. The binding between 
CD40L and CD40 modulates cellular immune responses 
by inducing the expression of costimulatory molecules that 
reside on antigen-presenting cells (APCs). Upregulation 
of costimulatory molecules lead to the activation of 
APCs, which in turn augment CD4+ T cell responses by 
increasing cytokine production, eventually leading to the 
activation of CD4+-dependent naive CD8+ T cells in vivo 
(Levin et al., 2017; Guan et al., 2017). 
Therefore, we combined G250 with CD40L to 
construct two plasmids, namely, pVAX1-G250 and 
pVAX1-CD40L, to improve the immunogenicities of the 
recombinant plasmids and evaluated the corresponding 
enhancements on anti-tumor immunity using a renal 
carcinoma model. 
In our mouse model,  immunization with a 
combination of the two DNA plasmids was found 
to be more effective in inhibiting tumor growth than 
immunization with either the antigen plasmid or the 
adjuvant plasmid alone. Analysis of the immune response 
showed that treatment with the combination of plasmids 
enhanced both the antibody and the T cell responses. 
Therefore, we hypothesized that the anti-tumor effects 
of the combination therapy was attributed to improved 
production of antigen-specific antibodies and stronger 
IFN-γ-mediated T cell responses in mice. However, 
the tumor growth inhibition rate was only 66% in the 
combination group, which indicated that the combined 
vaccination strategy elicited only a modest level of T cell 
immune response, since the cellular immune response 
to tumor clearance is thought to be crucial. Thus, further 
studies should investigate methods to further improve the 
potency of DNA vaccines in T cell priming, including 
optimization of the expression of certain T cell genes and 
improving compatibility with other adjuvant molecules.
Experimental results revealed that vaccination with 
both the pVAX1- G250 and pVAX1- CD40L induced 
strong immune responses and tumor suppression effects 
and especially enhanced the G250-specific T cell response. 
In the xenograft model, the combination treatment led to 
significantly stronger inhibition of tumor growth compared 
with the control group (the plasmid expressing G250 alone). 
CONCLUSION
In conclusion, our findings indicated that the use 
of CD40L as an adjuvant can effectively enhance the 
immunity and anti-tumor effects of a renal cell carcinoma 
vaccine. Our findings highlighted the promising use of 
CD40L for other types of tumor vaccines against tumor 
recurrence and metastasis.
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